Pulmatrix (PULM)
Dry-powder inhalation technology and clinical assets awaiting licensing or monetization.
Something off on this page? Send us feedback.
Holds a dry-powder inhalation platform and investigational respiratory, migraine, and antifungal assets, pursuing licenses and monetization rather than product sales. Operations rely on a pending merger and outside technical partners, with a contingent royalty tied to Cipla's potential overseas sales of PUR1900.
Operates as a virtual, pre-commercial biopharmaceutical company centered on the iSPERSE dry-powder particle-engineering platform and three investigational inhaled assets: PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for pulmonary fungal disease. The platform is designed to deliver small molecules or biologics to the lungs for local or systemic use.
Administers its business from Framingham, Massachusetts, with no physical facility and external development resources. Its potential economic routes are field licenses, development services, asset monetization, and a contingent royalty on Cipla's potential sales of PUR1900 outside the United States; its patents reach the United States and multiple foreign jurisdictions.
All legacy programs are unapproved and on hold or in monetization mode. Future operations are highly dependent on the pending merger with Eos SENOLYTIX, while technical work relies on outside partners, including MannKind and Cipla.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.2M · Total debt $0 · Total assets $3.2M · Shareholders' equity $2.6M
- Revenue
- $0
- Operating income
- −$1.0M
- Net income
- −$1.0M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 9.02% | 329.5K shares | |
| Otherremainder | 90.98% | 3.32M shares |
3.65M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Renaissance Technologies LLCInstitution | 2.99% | 109,148 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 1.50% | 54,899 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.22% | 44,629 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.92% | 33,594 | 13Fas of Mar 31, 2026 |
Sbi Securities Co., Ltd.Institution | 0.82% | 30,085 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Amneal Pharmaceuticals
Approved DHE autoinjector contests acute migraine treatment.
- Mereo BioPharma Group (ADR)
Clinical AECOPD program overlaps PUR1800's treatment field.
- Bausch Health
Migranal offers an established nasal DHE option for migraine.
- GSK (ADR)
Scaled inhaled COPD portfolio competes in pulmonary delivery.
- Insmed
Inhaled anti-infective and powder programs overlap lung delivery.
- Viatris
Systemic itraconazole and TOBI set pulmonary treatment alternatives.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pulmatrix | $1.47 | −3.61% | $5.4M | — | — | — | — |
| Amneal Pharmaceuticals | $18.01 | −0.33% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Mereo BioPharma Group (ADR) | $0.2651 | −0.75% | $42.7M | — | — | — | — |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| GSK (ADR) | $50.55 | +0.25% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Insmed | $126.96 | +0.22% | $27.45B | — | — | 24.1 | +296.1% |
| Viatris | $16.92 | −1.00% | $19.90B | — | 6.7 | 1.4 | +4.9% |
| Median | 26.4 | 7.9 | 1.8 | +9.9% |